Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say

For the quarter ended September 2024, Biogen Inc. (BIIB) reported revenue of $2.47 billion, down 2.6% over the same period last year. EPS came in at $4.08, compared to $4.36 in the year-ago quarter.The reported revenue represents a surprise of +0.92% over the Zacks Consensus Estimate of $2.44 billion. With the consensus EPS estimate being $3.77, the EPS surprise was +8.22%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Biogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- United States: $40.10 million versus $39.76 million estimated by 20 analysts on average. Compared to the year-ago quarter, this number represents a -31% change. Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- Rest of world: $192.70 million versus $191.48 million estimated by 20 analysts on average. Compared to the year-ago quarter, this number represents a +6.2% change. Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- United States: $227.50 million versus $214.82 million estimated by 20 analysts on average. Compared to the year-ago quarter, this number represents a -7.1% change. Revenue- Product- Rare Disease- SPINRAZA- Rest of World: $228.30 million compared to the $280.58 million average estimate based on 20 analysts. The reported number represents a change of -23.3% year over year. Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Total: $406.10 million versus the 23-analyst average estimate of $412.78 million. The reported number represents a year-over-year change of -11%. Revenue- Contract manufacturing, royalty and other revenue: $250.20 million versus the 23-analyst average estimate of $147.08 million. The reported number represents a year-over-year change of -17.8%. Revenue- Product- Rare Disease- SPINRAZA- Total: $381.40 million versus $434.55 million estimated by 23 analysts on average. Compared to the year-ago quarter, this number represents a -14.9% change. Revenue- Product- Rare Disease- SKYCLARYS- Total: $102.30 million versus $111.68 million estimated by 22 analysts on average. Revenue- Anti-CD20 therapeutic programs: $446.20 million versus the 22-analyst average estimate of $439.58 million. The reported number represents a year-over-year change of +6%. Revenue- Product, net: $1.77 billion versus $1.85 billion estimated by 22 analysts on average. Compared to the year-ago quarter, this number represents a -2% change. Revenue- Product- Biosimilars- Total: $196.60 million versus $202.40 million estimated by 21 analysts on average. Compared to the year-ago quarter, this number represents a +1.2% change. Revenue- Product- Multiple Sclerosis (MS)- Fumarate- VUMERITY- Total: $158.10 million compared to the $171.34 million average estimate based on 21 analysts. The reported number represents a change of -4.5% year over year. View all Key Company Metrics for Biogen here>>>Shares of Biogen have returned -3.8% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks